David Suhy

Earli, Inc. is a biotechnology company located in a biotech hub. The American company's mission is to make cancer a benign experience by catching and curing it early. Earli focuses on making cancer detectable and treatable at early stages through its novel "synthetic biopsies." By forcing cancer cells to produce synthetic biomarkers, they become highly detectable and localizable in a PET scanner, allowing for targeted treatment. Earli uses biology to force production of the synthetic biopsy, enabling massive signal amplification. The company was founded by Cyriac R. Roeding, David Suhy, and Sam Gambhir, with Cyriac R. Roeding serving as CEO since incorporation.

Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in Melbourne, Australia.

Tacere Therapeutics, Inc. provides treatment of infectious diseases. It develops novel therapeutics for the treatment of serious infectious diseases such as Hepatitis C (HCV). The company was founded by Sara M. Hall, Amit J. Kumar, John James Monahan, and Michael J. Catelani in 2006 and is headquartered in San Jose, CA.

Takara Bio USA, Inc. helps to accelerate the discovery process by providing pioneering tools that enable researchers to ask new questions and investigate ever more complex systems than was previously possible. With more than 5,000 literature citations, its innovative products and services continue to facilitate advancement in areas such as genomics, cancer research, apoptosis, cytogenetics, developmental genetics, cellular physiology, pharmocogenetics, and neurobiology.